Soiken Holdings Inc.
Stock Price Chart
2026/08/12 UpdatedPrice Trend
2026/08/12 UpdatedPrice & Trading Details
2026/08/12 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Dividend History 1Years Growth
Updated 2026/08/09| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥10 | +100.0% |
| 2025 | ¥5 | 0.0% |
| 2023 | ¥5 | 0.0% |
| 2022 | ¥5 | 0.0% |
| 2021 | ¥5 | - |
Financial Performance
2026/08/09 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥9,348M | ¥8,080M | ¥5,158M | ¥4,849M |
| Gross Profit | ¥4,260M | ¥3,716M | ¥2,482M | ¥2,410M |
| Operating Income | ¥1,209M | ¥726M | -¥610M | -¥138M |
| Pretax Income | ¥1,209M | ¥726M | -¥610M | -¥138M |
| Net Income | ¥810M | ¥452M | -¥662M | -¥211M |
| EPS | ¥30.95 | ¥17.27 | - | -¥8.05 |
| Operating Margin | 12.93% | 8.98% | -11.83% | -2.84% |
| Balance Sheet | ||||
| Total Assets | ¥8,490M | ¥8,240M | ¥6,946M | - |
| Total Equity | ¥6,648M | ¥6,969M | ¥6,233M | - |
| Total Liabilities | ¥1,842M | ¥1,271M | ¥713M | - |
| Cash | ¥6,017M | ¥5,946M | ¥4,790M | - |
| Interest-bearing Debt | - | - | - | - |
| Equity Ratio | 78.31% | 84.57% | 89.73% | 0.00% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥2,136M | -¥102M | -¥881M | - |
| Investing CF | -¥245M | ¥160M | -¥14M | - |
| Financing CF | -¥130M | -¥130M | -¥261M | - |
| Free CF | ¥2,091M | -¥141M | -¥895M | - |
| Efficiency | ||||
| ROE | 12.18% | 6.48% | -10.62% | 0.00% |
| ROA | 9.54% | 5.48% | -9.53% | 0.00% |
Latest IR Information
-
Financial Summary for the Fiscal Year Ending June 2026 (Japanese GAAP) (Consolidated)
For the fiscal year ending June 2026, consolidated net sales were 387.1 million yen, operating income was 275 million yen, and net income attributable to owners of the parent was 212 million yen. Full-year guidance is net sales of 3,270...
Read more -
Notice regarding the differences between the consolidated full-year earnings forecast for the year ending June 2026 and actual results
Full-year consolidated earnings forecast for the year ending June 2026 was raised. Revenue from 3,860 million yen to 3,871 million yen; operating income from -180 million yen to 275 million yen; and other segment adjustments. Profitability improvements are progressing in...
Read more -
Notice of Dissolution of Subsidiary
The news reports the resolution to dissolve BB Laboratories (BBL), the subsidiary. All business to be terminated by March 31, 2026, liquidation not yet decided, and financial impact expected to be minor in the fiscal year ending June 2027.
Read more -
Notice of Change in Reported Segments
Announces restructuring of the business portfolio and changes to reported segments. Positions Health Care Platform as the core, renaming the Corporate Health Care Support business. Integrates cosmetics and functional materials development into Japan Preventive Medicine Co., Ltd. to form a...
Read more -
Notice Regarding Compliance with Listing Maintenance Standards
Read more
Latest News (5 items)
Company Information
About
Soiken Holdings Inc. engages in the development of biomarkers in Japan. It is involved in the development and sale of cosmetics and dietary supplements comprising imidapeptides; licensing and development of biomarker technology; provision of marketing research and post-marketing surveys for dietary supplements; and research, development, and sale of functional materials, such as lactoferrin, as well as pharmaceutical products from ascochlorin derivatives. The company also provides clinical evaluation tests for foodstuffs using biomarker technology; support for pharmaceutical clinical research and epidemiology studies; and services to health insurance societies, including contracted health guidance, specific health checkup promotion services for the dependents of insured, and service to prevent diabetes. Soiken Holdings Inc. was incorporated in 1994 and is headquartered in Toyonaka, Japan.
